Importantly, CXCR2 inhibitors produce reversible reductions in the number of circulating and tissue neutrophils within 24 h in humans [99], demonstrating the pharmacodynamic feasibility of targeting this pathway; however, the clinical efficacy and safety of their use in ACD are still not clear [98,99,100,101,102]. The gene discussed is CXCR2; the disease is granular corneal dystrophy type II.